0329 GMT - Pro Medicus's bulls at Goldman Sachs lift their earnings forecasts for the next two full fiscal years following the Australian imaging-tech provider's latest contract wins. The GS analysts make no change to their forecast of 38% earnings growth in the current 2025 fiscal year, but lift expectations by 2% for fiscal 2026 and by 4% for fiscal 2027. They tell clients in a note that they don't anticipate any guidance to be provided with the company's first-half result announcement, but do expect positive commentary on the strength of its contract pipeline. GS lifts its target price by 8.9% to A$310.00 and keeps a buy rating on the stock. Shares are up 1.25% at A$287.48. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
February 04, 2025 22:29 ET (03:29 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。